González-Juanatey, J RAnguita-Sánchez, MBayes-Genís, AComín-Colet, JGarcía-Quintana, ARecio-Mayoral, AZamorano-Gómez, J LCepeda-Rodrigo, J MManzano, L2023-05-032023-05-032022-04-23http://hdl.handle.net/10668/22488Despite currently available treatments, risk of death and hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF) remains high. The pathophysiology of HFrEF includes neurohormonal activation characterized by stimulation of deleterious pathways (i.e., sympathetic nervous and renin-angiotensin-aldosterone systems) and suppression of protective pathways such as nitric oxide-dependent pathways. Inhibition or stimulation of some, but not all, of these pathways is insufficient. In HFrEF, there is reduced nitric oxide, soluble guanylate cyclase, and cGMP activity, leading to deleterious effects in the myocardial, vascular, and renal systems. Vericiguat is able to stimulate the activity of this protective pathway. The VICTORIA study demonstrated that the addition of vericiguat to optimal medical treatment in patients with HFrEF and recent decompensation significantly reduced the incidence of the primary endpoint, a composite of cardiovascular death or HF hospitalization, with a number needed to treat of 24 patients and excellent tolerability.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/GMPcHeart failureInsuficiencia cardíacaNitric oxideVericiguatcGMPÓxido nítricoHeart FailureHeterocyclic Compounds, 2-RingHumansNitric OxidePyrimidinesStroke VolumeVentricular Dysfunction, Leftresearch article35473692open access10.1016/j.rceng.2021.12.0062254-8874https://doi.org/10.1016/j.rceng.2021.12.006